Managers / Q1 2026
NVIDIA CORP
CIK 0001045810 · 2788 SAN TOMAS EXPRESSWAY, SANTA CLARA, CA, 95051 · 408-486-2000
Summary
Nvidia Corp reported $18.4B in U.S.-listed holdings across 7 positions for Q1 2026.
The portfolio is heavily concentrated: INTC alone accounts for 51.6% of reported value.
Compared with Q4 2025, the fund opened 2 new positions and exited 0.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 92.0% · $16.9B
- ADR · 7.3% · $1.3B
- Other · 0.7% · $124M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2025 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| COHRCOHERENT CORP | NEW | +7.79M | 7.79M | +$1.9B | $1.9B |
| GENBGENERATE BIOMEDICINES INC | NEW | +833.3K | 833.3K | +$10M | $10M |
| CRWVCOREWEAVE INC | ADDED | +22.94M | 47.21M | +$1.9B | $3.7B |
| INTCINTEL CORP | HELD | +0 | 214.78M | +$1.6B | $9.5B |
| SNPSSYNOPSYS INC | HELD | +0 | 4.82M | −$353M | $1.9B |
| NOKNOKIA CORP | HELD | +0 | 166.39M | +$261M | $1.3B |
| NEBIUS GROUP N.V. | HELD | +0 | 1.19M | +$24M | $124M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2026
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | INTCINTEL CORPhistory → | COM | 51.58% | $9.5B | 214.78M |
| 2 | CRWVCOREWEAVE INChistory → | COM CL A | 19.91% | $3.7B | 47.21M |
| 3 | SNPSSYNOPSYS INChistory → | COM | 10.40% | $1.9B | 4.82M |
| 4 | COHRCOHERENT CORPhistory → | COM | 10.10% | $1.9B | 7.79M |
| 5 | NOKNOKIA CORPhistory → | SPONSORED ADR | 7.28% | $1.3B | 166.39M |
| 6 | NEBIUS GROUP N.V. | SHS CLASS A | 0.67% | $124M | 1.19M |
| 7 | GENBGENERATE BIOMEDICINES INChistory → | COM SHS | 0.06% | $10M | 833.3K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $18.4B | 7 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $13.1B | 5 | Feb 17, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $3.8B | 6 | Nov 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $4.3B | 6 | Aug 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $1.1B | 6 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $305M | 5 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $433M | 6 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $393M | 5 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $333M | 4 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $230M | 5 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.